Skip to main content
SpringerLink
Log in

Ticagrelor: A Review of Its Use in Adults with Acute Coronary Syndromes

  • Adis Drug Evaluation
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Ticagrelor (Brilique™, Brilinta®), a cyclopentyl-triazolopyrimidine, is an orally active, reversible, and selective adenosine diphosphate (ADP) receptor antagonist indicated for use in patients with acute coronary syndromes (ACS). Ticagrelor has a faster onset of action and provides greater inhibition of platelet aggregation than clopidogrel. In the large well-designed, PLATO study in adult patients with ACS, 12 months’ treatment with ticagrelor was more effective than clopidogrel in reducing the incidence of the primary composite endpoint of myocardial infarction, stroke, or cardiovascular (CV) death. Ticagrelor also reduced all-cause mortality relative to clopidogrel, although statistical significance of this was not confirmed in hierarchical testing. Benefit with ticagrelor was seen both in invasively and noninvasively managed patients. Ticagrelor was generally well tolerated and was not associated with an increased risk of major bleeding relative to clopidogrel. However, the incidences of non-coronary artery bypass grafting (CABG)-related bleeding, and major or minor bleeding, as well as some non-hemorrhagic adverse events, including dyspnea (usually of mild or moderate severity) and ventricular pauses (largely asymptomatic) were higher with ticagrelor. In addition, the ATLANTIC study showed that although pre-hospital administration of ticagrelor did not improve pre-percutaneous coronary intervention (PCI) coronary reperfusion in ACS patients relative to in-hospital administration, ticagrelor was safe in both instances, with no significant between-group differences in non-CABG-related major and minor bleeding events. Although further comparative studies with other antiplatelet agents, including prasugrel, are required to position it more definitively, current evidence indicates that ticagrelor is a useful option for the prevention of thrombotic CV events in ACS patients managed invasively or noninvasively.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Siller-Matula JM, Krumphuber J, Jilma B. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. Br J Pharmacol. 2010;159(3):502–17.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Angiolillo DJ. The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012;72(16):2087–116.

    Article  CAS  PubMed  Google Scholar 

  3. Varenhorst C, James S. Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)? Curr Cardiol Rep. 2012;14(4):486–92.

    Article  PubMed  Google Scholar 

  4. Tapp L, Shantsila E, Lip GYH. Role of ticagrelor in clopidogrel nonresponders: resistance is futile? Circulation. 2010;121(10):1169–71.

    Article  PubMed  Google Scholar 

  5. Bassand J-P. Unmet needs in antiplatelet therapy. Eur Heart J Suppl. 2008;10(Suppl D):D3–11.

    Article  CAS  Google Scholar 

  6. Plosker GL, Lyseng-Williamson KA. Clopidogrel: a review of its use in the prevention of thrombosis. Drugs. 2007;67(4):613–46.

    Article  CAS  PubMed  Google Scholar 

  7. Sadanandan S, Singh IM. Clopidogrel: the data, the experience, and the controversies. Am J Cardiovasc Drugs. 2012;12(6):361–74.

    Article  CAS  PubMed  Google Scholar 

  8. Teng R. Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor. Clin Pharmacokinet. 2012;51(5):305–18.

    Article  CAS  PubMed  Google Scholar 

  9. Van Giezen JJJ, Nilsson L, Berntsson P, et al. Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost. 2009;7(9):1556–65.

    Article  Google Scholar 

  10. Deeks ED. Ticagrelor: a review of its use in the management of acute coronary syndromes. Drugs. 2011;71(7):909–33.

    Article  CAS  PubMed  Google Scholar 

  11. European Medicines Agency. Brilique (ticagrelor) 90 mg film-coated tablets: summary of product characteristics. 2014. http://www.ema.europa.eu/. Accessed 28 Jan 2015.

  12. Iyu D, Glenn JR, White AE, et al. Mode of action of P2Y12 antagonists as inhibitors of platelet function. Thromb Haemost. 2011;105(1):96–106.

    Article  CAS  PubMed  Google Scholar 

  13. Astrazeneca. Brilinta (ticagrelor): US prescribing information. 2014. http://www.accessdata.fda.gov. Accessed 28 Jan 2015.

  14. Nylander S, Femia EA, Scavone M, et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. J Thromb Haemost. 2013;11(10):1867–76.

    CAS  PubMed  Google Scholar 

  15. Bonello L, Laine M, Kipson N, et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol. 2014;63(9):872–7.

    Article  CAS  PubMed  Google Scholar 

  16. Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Am Coll Cardiol. 2013;61(7):723–7.

    Article  CAS  PubMed  Google Scholar 

  17. Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol. 2014;63(23):2503–9.

    Article  CAS  PubMed  Google Scholar 

  18. Storey RF, Becker RC, Harrington RA, et al. Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the platelet inhibition and patient outcomes [PLATO] pulmonary function substudy). Am J Cardiol. 2011;108(11):1542–6.

    Article  CAS  PubMed  Google Scholar 

  19. Storey RF, Bliden KP, Patil SB, et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol. 2010;56(3):185–93.

    Article  CAS  PubMed  Google Scholar 

  20. Storey RF, James SK, Siegbahn A, et al. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets. 2013;25(7):517–25.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Akerblom A, Wallentin L, Siegbahn A, et al. Serial renal function assessment with cystatin C in patients with acute coronary syndrome randomized to ticagrelor or clopidogrel [abstract no. P2439]. Eur Heart J. 2011;32(Suppl 1):417.

    Google Scholar 

  22. Butler K, Wei C, Teng R. Single-dose ticagrelor does not prolong the QT interval in healthy subjects. Int J Clin Pharmacol Ther. 2010;48(10):643–51.

    Article  CAS  PubMed  Google Scholar 

  23. Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 2010;66(5):487–96.

    Article  CAS  PubMed  Google Scholar 

  24. Aradi D, Horvath I, Kittka B, et al. Impact of clinical presentation on platelet inhibition by ticagrelor compared to clopidogrel: insights from a single-center cohort of the PLATO trial [abstract no. TCT-741]. J Am Coll Cardiol. 2012;60(17 Suppl):B216.

    Article  Google Scholar 

  25. Montalescot G, van’t Hof AW, Lapostolle F. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014;371(11):1016–27.

    Article  CAS  PubMed  Google Scholar 

  26. Parodi G, Xanthopoulou I, Bellandi B. Ticagrelor crushed tablets administration in STEMI patients: the Mashed Or Just Integral Tablets of ticagrelOr (MOJITO) study [abstract no. 5800]. Eur Heart J. 2014;35(Abstract Suppl):1030.

    Google Scholar 

  27. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27(9):1038–47.

    Article  CAS  PubMed  Google Scholar 

  28. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50(19):1844–51.

    Article  CAS  PubMed  Google Scholar 

  29. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50(19):1852–6.

    Article  CAS  PubMed  Google Scholar 

  30. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120(25):2577–85.

    Article  CAS  PubMed  Google Scholar 

  31. Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121(10):1188–99.

    Article  CAS  PubMed  Google Scholar 

  32. Tantry US, Bliden KP, Wei C, et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet. 2010;3(6):556–66.

    Article  CAS  PubMed  Google Scholar 

  33. Hibbert B, Maze R, Pourdjabbar A, et al. A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD study. PloS One [Electronic Resource]. 2014;9(3):e92078.

    Article  PubMed Central  PubMed  Google Scholar 

  34. Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol. 2013;61(15):1601–6.

    Article  CAS  PubMed  Google Scholar 

  35. Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circulation. 2012;5(6):797–804.

    CAS  PubMed  Google Scholar 

  36. Laine M, Frere C, Toesca R, et al. Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome: a pharmacodynamic randomised study. Thromb Haemost. 2014;111(2):273–8.

    Article  CAS  PubMed  Google Scholar 

  37. Alexopoulos D, Stavrou K, Koniari I, et al. Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events. Thromb Haemost. 2014;112(3):551–7.

    Article  CAS  PubMed  Google Scholar 

  38. Alexopoulos D, Xanthopoulou I, Mavronasiou E, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes. Diabetes Care. 2013;36(8):2211–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  39. Alexopoulos D, Galati A, Xanthopoulou I, et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol. 2012;60(3):193–9.

    Article  CAS  PubMed  Google Scholar 

  40. Teng R, Carlson G, Hsia J, et al. Crushing ticagrelor tablets accelerates exposure compared with intact tablets [abstract no. A229]. J Am Coll Cardiol. 2014;63(12).

  41. Hiasa Y, Teng R, Emanuelsson H. Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease. Cardiovasc Interv Ther. 2014;29(4):324–33.

    Article  CAS  PubMed  Google Scholar 

  42. Teng R, Butler K. A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. Eur J Clin Pharmacol. 2013;69(10):1801–8.

    Article  CAS  PubMed  Google Scholar 

  43. Teng R, Maya J, Butler K. Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers. Platelets. 2013;24(8):615–24.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  44. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.

    Article  CAS  PubMed  Google Scholar 

  45. James S, Åkerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2009;157(4):599–605.

    Article  CAS  PubMed  Google Scholar 

  46. Mahaffey KW, Held C, Wojdyla DM, et al. Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2014;63(15):1493–9.

    Article  CAS  PubMed  Google Scholar 

  47. Levin LA, Wallentin L, Bernfort L, et al. Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes: results from the PLATO trial. Value Health. 2013;16(4):574–80.

    Article  PubMed  Google Scholar 

  48. Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011;124(5):544–54.

    Article  CAS  PubMed  Google Scholar 

  49. Nanhwan MK, Ling S, Kodakandla M, et al. Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect. Arterioscler Thromb Vasc Biol. 2014;34(9):2078–85.

    Article  CAS  PubMed  Google Scholar 

  50. James SK, Roe MT, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ [Electronic Resource]. 2011;342:d3527.

    PubMed Central  PubMed  Google Scholar 

  51. Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375(9711):283–93.

    Article  CAS  PubMed  Google Scholar 

  52. Steg PG, Harrington RA, Emanuelsson H, et al. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation. 2013;128(10):1055–65.

    Article  CAS  PubMed  Google Scholar 

  53. Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010;122(21):2131–41.

    Article  PubMed  Google Scholar 

  54. Held C, Åsenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011;57(6):672–84.

    Article  CAS  PubMed  Google Scholar 

  55. James SK, Storey RF, Khurmi NS, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation. 2012;125(23):2914–21.

    Article  CAS  PubMed  Google Scholar 

  56. Lindholm D, Varenhorst C, Cannon CP, et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J. 2014;35(31):2083–93.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  57. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;130(25):2354–94.

    Article  PubMed  Google Scholar 

  58. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999–3054.

    Article  PubMed  Google Scholar 

  59. Wallentin L, Lindholm D, Siegbahn A, et al. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the prospective randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2014;129(3):293–303.

    Article  CAS  PubMed  Google Scholar 

  60. Varenhorst C, Alstrom U, Braun OO, et al. Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. Heart. 2014;100(22):1762–9.

    Article  CAS  PubMed  Google Scholar 

  61. Varenhorst C, Alstrom U, Scirica BM, et al. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol. 2012;60(17):1623–30.

    Article  PubMed  Google Scholar 

  62. Kohli P, Wallentin L, Reyes E, et al. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO study. Circulation. 2013;127(6):673–80.

    Article  CAS  PubMed  Google Scholar 

  63. Armstrong PW, Siha H, Fu Y, et al. ST-elevation acute coronary syndromes in PLATO: insights from the ECG substudy. Circulation. 2011;125(3):514–21.

    Article  PubMed  Google Scholar 

  64. Armstrong PW, Westerhout CM, Fu Y, et al. Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy. Am J Med. 2013;126(8):723–9.e1.

  65. Kunadian V, James SK, Wojdyla DM, et al. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). JACC. 2013;6(7):671–83.

    Article  PubMed  Google Scholar 

  66. Goodman SG, Clare R, Pieper KS, et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 2012;125(8):978–86.

    Article  CAS  PubMed  Google Scholar 

  67. Bansilal S, Wiviott S, Becker R, et al. The efficacy and safety of ticagrelor as compared to clopidogrel, with and without a glycoprotein IIB/IIIA inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a PLATO (study of platelet inhibition and patient outcomes) analysis [abstract no. 2909-3]. J Am Coll Cardiol. 2013;61(10):E1858.

    Article  Google Scholar 

  68. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376(9749):1320–8.

    Article  CAS  PubMed  Google Scholar 

  69. Wallentin L, James S, Storey R, et al. Greater efficacy of ticagrelor compared to clopidogrel in acute coronary syndrome is not driven by outcomes in poor metabolizers of clopidogrel [abstract no. 1164-80]. J Am Coll Cardiol. 2012;59(13):E500.

    Article  Google Scholar 

  70. Montalescot G, Lassen JF, Hamm CW, et al. Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind administration of ticagrelor in the cath lab or in the ambulance for new ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study. Am Heart J. 2013;165(4):515–22.

    Article  PubMed  Google Scholar 

  71. Becker RC, Bassand JP, Budaj A, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2011;32(23):2933–44.

    Article  CAS  PubMed  Google Scholar 

  72. Kang HJ, Clare RM, Gao R, et al. Net clinical benefits of ticagrelor compared with clopidogrel in asian acute coronary syndrome patients: a PLATO sub-study [abstract no. 17001]. Circulation. 2013;128(22 Suppl 1).

  73. Husted S, James S, Becker RC, et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circulation. 2012;5(5):680–8.

    PubMed  Google Scholar 

  74. Husted S, James SK, Bach RG, et al. The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2014;35(23):1541–50.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  75. Brilakis ES, Held C, Meier B, et al. Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial. Am Heart J. 2013;166(3):474–80.

    Article  CAS  PubMed  Google Scholar 

  76. James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2010;31(24):3006–16.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  77. Kotsia A, Brilakis ES, Held C, et al. Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2014;168(1):68–75.e2.

  78. Patel MR, Becker RC, Wojdyla DM, et al. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: data from the PLATO trial. Eur J Prev Cardiol. 2014. doi:10.1177/2047487314533215.

  79. Storey RF, Becker RC, Harrington RA, et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J. 2011;32(23):2945–53.

    Article  CAS  PubMed  Google Scholar 

  80. Scirica BM, Cannon CP, Emanuelsson H, et al. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. J Am Coll Cardiol. 2011;57(19):1908–16.

    Article  CAS  PubMed  Google Scholar 

  81. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):529–55.

    Article  PubMed  Google Scholar 

  82. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569–619.

    Article  CAS  PubMed  Google Scholar 

  83. National Institute for Health and Care Excellence. Myocardial infarction with ST-segment elevation: the acute management of myocardial infarction with ST-segment elevation. 2013. http://www.nice.org.uk/guidance/cg167. Accessed 28 Jan 2015.

  84. Serebruany VL. Ticagrelor FDA approval issues revisited. Cardiology (Switzerland). 2012;122(3):144–7.

    CAS  Google Scholar 

  85. DiNicolantonio JJ, Tomek A. Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel. Int J Cardiol. 2013;169(2):145–6.

    Article  PubMed  Google Scholar 

  86. Wallentin L, Becker RC, Cannon CP, et al. No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial. Int J Cardiol. 2014;176(1):300–2.

    Article  PubMed  Google Scholar 

  87. Wallentin L, Becker RC, Cannon CP, et al. Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome. Int J Cardiol. 2014;170(3):e59–62.

    Article  PubMed  Google Scholar 

  88. AstraZeneca. United States Department of Justice closes investigation into PLATO clinical trial for Brilinta [media release]. 16 Oct 2014. http://www.astrazeneca.com.

  89. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.

    Article  CAS  PubMed  Google Scholar 

  90. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502.

    Article  CAS  PubMed  Google Scholar 

  91. Schomig A. Ticagrelor: is there need for a new player in the antiplatelet-therapy field? N Engl J Med. 2009;361(11):1108–11.

    Article  PubMed  Google Scholar 

  92. Schneider DJ. Mechanisms potentially contributing to the reduction in mortality associated with ticagrelor therapy. J Am Coll Cardiol. 2011;57(6):685–7.

    Article  CAS  PubMed  Google Scholar 

  93. Belchikov YG, Koenig SJ, DiPasquale EM. Potential role of endogenous adenosine in ticagrelor-induced dyspnea. Pharmacotherapy. 2013;33(8):882–7.

    Article  CAS  PubMed  Google Scholar 

  94. Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367(14):1297–309.

    Article  CAS  PubMed  Google Scholar 

  95. Schulz S, Angiolillo DJ, Antoniucci D, et al. Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy - design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 trial. J Cardiovasc Transl Res. 2014;7(1):91–100.

    Article  PubMed  Google Scholar 

  96. National Institute for Health and Care Excellence. Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182). 2014. http://www.nice.org.uk/guidance/ta317/. Accessed 28 Jan 2015.

  97. Bonaca MP, Bhatt DL, Braunwald E, et al. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J. 2014;167:437–44.

    Article  PubMed  Google Scholar 

  98. Steg PG. PLATO: impact on the management of acute coronary syndromes and the future of PARTHENON [oral presentation]. In: European Society of Cardiology annual congress. 2014.

  99. Lyseng-Williamson KA. Ticagrelor: a review of its cost effectiveness in the management of acute coronary syndromes. Drugs Ther Perspect. 2013;29(12):379–86.

    Article  Google Scholar 

  100. Janzon M, James S, Cannon CP, et al. Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy. Heart. 2014;101(2):119–25.

    Article  PubMed Central  PubMed  Google Scholar 

  101. Gasche D, Ulle T, Meier B, et al. Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland. Swiss Med Wkly [Electronic Resource]. 2013;143:w13851.

    PubMed  Google Scholar 

  102. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010;122(11):1056–67.

    Article  PubMed  Google Scholar 

  103. Cornel JH, Becker RC, Goodman SG, et al. Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2012;164(3):334–42.e1.

  104. de Souza Brito F, Akerbolm AA, Wojdyla D. Efficacy and safety of ticagrelor in patients with acute coronary syndrome and heart failure: insights from the platelet inhibition and patient outcomes (PLATO) trial [abstract no. 1128 plus oral presentation]. Eur Heart J. 2014;35(Abstract Suppl):202–3.

    Google Scholar 

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit. Sohita Dhillon is a salaried employee of Adis/Springer.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Sohita Dhillon

Authors
  1. Sohita Dhillon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sohita Dhillon.

Additional information

The manuscript was reviewed by: F. Fernandez-Aviles, Department of Cardiology, Servicio de Cardiologia, Hospital Universitario Gregorio Marañon, Complutense University - School of Medicine, Madrid, Spain; A. M. Lincoff, Department of Cardiovascular Medicine, The Cleveland Clinic, Cleveland, OH, USA; D. J. Schneider, Department of Medicine, Cardiovascular Research Institute, University of Vermont, Burlington, VT, USA; L. Wallentin, Department of Medical Sciences and Cardiology, Uppsala Clinical Research Center, University Hospital, Uppsala, Sweden.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dhillon, S. Ticagrelor: A Review of Its Use in Adults with Acute Coronary Syndromes. Am J Cardiovasc Drugs 15, 51–68 (2015). https://doi.org/10.1007/s40256-015-0108-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40256-015-0108-5

Keywords

Search

Navigation